Author: Zacks Small Cap Research

123459730 / 966 POSTS
By Ann Heffron, CFA, CPAOTC:CPKF READ THE FULL CPKF RESEARCH REPORT Chesapeake Financial’s (OTC:CPKF) second quarter net earnings fell $1.2 million, or 37%, year over year to $2.1 million, while 2020’s second quarter diluted EPS decreased by $0.24, o ...
By Beth Senko, CFANASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT We are raising our target valuation for EyeGate Pharmaceuticals (NASDAQ:EYEG) from $12.00 to $15.00 based on solid progress in its existing pipeline and the introduction of a new candid ...
By John Vandermosten, CFANASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT DarioHealth (NASDAQ:DRIO) and HMC HealthWorks announced that they had entered into a sales and distribution partnership. HMC will incorporate DarioHealth’s digital therapeutics ( ...
By John Vandermosten, CFANASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International, Inc. (NASDAQ:DYAI) and VTT have developed a production platform that boasts higher efficiency and lower cost based on Dyadic’s C1, Thermothelomyces heteroth ...
By John Vandermosten, CFAEPA:ALQGC | OTCQX:QNNTF READ THE FULL ALQGC RESEARCH REPORT Exclusive Licensing and Collaboration Agreement On September 22, 2020, Quantum Genomics (EPA:ALQGC) (OTCQX:QNNTF) announced that it had entered into an exclusive lic ...
By Ian Gilson, PhD, CFANASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio Innovations (NASDAQ:MBII) has announced the formation of a strategic alliance in South America with Rizobacter, a subsidiary of Bioceres Solutions Inc. (NYSE: BIOX $5.6 ...
By M. MarinNASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a clinical-stage pharmaceutical company with a proprietary oral protein delivery platform technology, is getting ready to initiate two Phase 3 clinic ...
By John Vandermosten, CFANASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT On September 18, 2020, two presentations related to Achieve Life Sciences (NASDAQ:ACHV) were given at the Society for Research on Nicotine and Tobacco European (SRNT-E) Annual Me ...
By David Bautz, PhDNASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT We are initiating coverage of Qualigen Therapeutics, Inc. (NASDAQ:QLGN) with a valuation of $10.00. Qualigen is a biopharmaceutical company developing novel treatments for cancer and i ...
By David Bautz, PhDNASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Positive Interim Data for ARO-AAT On September 16, 2020, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced interim 24-week biopsy data for four patients from AROA ...
123459730 / 966 POSTS